Chemical differentiation of type I and type II receptors for adrenal steroids in brain cytosol.
Studies outlined here compare the properties of mineralocorticoid (Type I) and glucocorticoid (Type II) receptors in cytosol from adrenalectomized mouse brain. Pretreating cytosol with dextran-coated charcoal (DCC) produced a 4.7-fold increase in the subsequent macromolecular binding of the mineralocorticoid, [3H]aldosterone (20 nM ALDO, in the presence of a 50-fold molar excess of the highly specific synthetic glucocorticoid, RU 26988), whereas it produced a 55% decrease in the binding of the glucocorticoid, [3H]triamcinolone acetonide (20 nM TA). Scatchard analyses revealed that DCC pretreatment had no effect on the affinity or maximal binding of Type I receptors for [3H]ALDO (in the presence of a 0-, 50- or 500-fold excess of RU 26988), whereas it produced a 3- to 6-fold increase in the Kd, and an 8-43% decrease in the maximal binding, of Type II receptors for [3H]TA and [3H]dexamethasone. Optimal stability of unoccupied Type I receptors at 0 degree C was found to be achieved in buffers containing glycerol, but lacking molybdate. Although the addition of molybdate was found to reduce the loss in Type I receptor binding observed after incubating unlabelled cytosol at 12 or 22 degrees C, this stabilization was accompanied by a concentration-dependent reduction in the binding of [3H]ALDO at 0 degree C. Scatchard analyses showed that this reduction was due to a shift in the maximal binding, and not the affinity, of the Type I receptors for [3H]ALDO. The presence or absence of dithiothreitol in cytosol appeared to have little effect on the stability of Type I receptors. In contrast to our finding for Type I receptors, it was possible to stabilize the binding capacity of unoccupied Type II receptors, even after 2-4 h at 12 or 22 degrees C, if the glycerol containing buffers were supplemented with both molybdate and dithiothreitol. In summary, these results indicate distinct chemical differences between Type I and Type II receptors for adrenal steroids.
D000315:Adrenalectomy; D000450:Aldosterone / Q000378:metabolism; D000732:Androstanols / Q000378:metabolism; D001923:Brain Chemistry; D002606:Charcoal; D003600:Cytosol / Q000032:analysis*; D003907:Dexamethasone / Q000378:metabolism; D003911:Dextrans; D004229:Dithiothreitol / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D007700:Kinetics; D008982:Molybdenum / Q000494:pharmacology; D011965:Receptors, Glucocorticoid / Q000032:analysis*; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid / Q000032:analysis*; D014222:Triamcinolone Acetonide / Q000378:metabolism
D000732:Androstanols; D003911:Dextrans; D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid; C044659:molybdate; D002606:Charcoal; D000450:Aldosterone; C038341:RU 26988; D003907:Dexamethasone; D008982:Molybdenum; D004492:Edetic Acid; D014222:Triamcinolone Acetonide; D004229:Dithiothreitol